The first structure of a bacterial diterpene cyclase: CotB2. (1st June 2014)

• Record Type: Journal Article
• Authors: Janke, Ronja; Görner, Christian; Hirte, Max; Brück, Thomas; Loll, Bernhard
• Is Part Of: Acta crystallographica. Volume 70:Part 6(2014:Jun.)
• Page Start: 1528
• Page End: 1537
• Publication Date: 2014-06-01
• Subjects: Biomolecules -- Structure -- Periodicals; Physical biochemistry -- Periodicals; X-ray crystallography -- Periodicals; Crystallography -- Periodicals; 572
• DOI: 10.1107/S1399004714005513
• Languages: English
• ISSNs: 0907-4449

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Sesquiterpenes and diterpenes are a diverse class of secondary metabolites that are predominantly derived from plants and some prokaryotes. The properties of these natural products encompass antitumor, antibiotic and even insecticidal activities. Therefore, they are interesting commercial targets for the chemical and pharmaceutical industries. Owing to their structural complexity, these compounds are more efficiently accessed by metabolic engineering of microbial systems than by chemical synthesis. This work presents the first crystal structure of a bacterial diterpene cyclase, CotB2 from the soil bacterium <italic>Streptomyces melanosporofaciens</italic>, at 1.64 Å resolution. CotB2 is a diterpene cyclase that catalyzes the cyclization of the linear geranylgeranyl diphosphate to the tricyclic cyclooctat‐9‐en‐7‐ol. The subsequent oxidation of cyclooctat‐9‐en‐7‐ol by two cytochrome P450 monooxygenases leads to bioactive cyclooctatin. Plasticity residues that decorate the active site of CotB2 have been mutated, resulting in alternative monocyclic, dicyclic and tricyclic compounds that show bioactivity. These new compounds shed new light on diterpene cyclase reaction mechanisms. Furthermore, the product of mutant CotB2<sup>W288G</sup> produced the new antibiotic compound (1<italic>R</italic>, 3<italic>E</italic>, 7<italic>E</italic>, 11<italic>S</italic>, 12<italic>S</italic>)‐3, 7, 18‐dolabellatriene, which acts specifically against multidrug‐resistant <italic>Staphylococcus aureus</italic>. This opens a sustainable route for the industrial‐scale production of this bioactive compound.</p> </abstract>